Generic Medicine Info
Should be taken on an empty stomach. Best taken on an empty stomach 1 hr before or 2 hr after meals. May be taken w/ meals to reduce GI discomfort.
Hypersensitivity. Patient w/ acute liver disease or a history of isoniazid-associated hepatic injury.
Special Precautions
Patient w/ convulsive disorders, history of psychosis. Patient at risk of neuropathy (e.g. diabetics, alcoholics, malnourished, uraemic, infected w/ HIV) or pyridoxine deficiency. Hepatic and severe renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor baseline and periodic LFTs (ALT and AST), sputum cultures mthly until 2 consecutive negative cultures reported and prodromal signs of hepatitis.
Adverse Reactions
Peripheral neuritis, psychotic reactions, convulsions, optic neuritis, transient increases in liver enzymes; haematological effects (e.g. anaemias, agranulocytosis, thrombocytopenia, eosinophilia); hypersensitivity reactions include skin eruptions (including erythema multiforme), fever, vasculitis; nausea, vomiting, dry mouth, constipation, pellagra, purpura, hyperglycaemia, lupus-like syndrome, vertigo, hyperreflexia, urinary retention, gynaecomastia.
Potentially Fatal: Hepatitis.
Drug Interactions
Inhibit the hepatic metabolism of antiepileptics (e.g. carbamazepine, ethosuximide, primidone, phenytoin), benzodiazepines (e.g. diazepam, triazolam), chlorzoxazone, theophylline, disulfiram, sometimes leading to increased toxicity. Increased metabolism of enflurane, resulting in potentially nephrotoxic levels of fluoride. Increased concentrations and enhanced effects or toxicity of clofazimine, cycloserine and warfarin. Reduced absorption w/ Al-containing antacids. Increased risk of peripheral neuropathy w/ zalcitabine and stavudine.
CIMS Class
ATC Classification
J04AC01 - isoniazid ; Belongs to the class of hydrazides. Used in the systemic treatment of tuberculosis.
Disclaimer: This information is independently developed by CIMS based on isoniazid from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in